PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
https://doi.org/10.20996/1819-6446-2013-9-5-551-556
Abstract
Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors that influence the choice of dabigatran dose in different individuals are discussed. Dabigatran treatment in special conditions is considered: during stroke development; in electrical or pharmacological cardioversion; in invasive or surgical procedures; during bleeding. Possible organizational system of thromboembolic events prevention in patients with atrial fibrillation is presented.
About the Authors
E. D. Kosmacheva
Kuban State Medical University, Krasnodar
Russian Federation
Russian Federation
S. G. Kanorskiy
Kuban State Medical University, Krasnodar
Russian Federation
Russian Federation
A. A. Kastanayan
Rostov State Medical University, Rostov-on-Don
Russian Federation
Russian Federation
N. V. Haylo
Rostov State Medical University, Rostov-on-Don
Russian Federation
Russian Federation
D. B. Goltyapin
“Heart Department” Clinic, Stavropol
Russian Federation
Russian Federation
E. A. Lipnitskaya
Astrakhan State Medical Academy, Astrakhan
Russian Federation
Russian Federation
M. E. Statsenko
Volgograd State Medical University, Volgograd
Russian Federation
Russian Federation
References
1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.
2. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 147: 1561-4.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
5. Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis 2011; 31: 249-58.
6. Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-45.
7. Weitz JI. Meeting the unmet needs in anticoagulant therapy. Eur J Haematol 2010; 85 (Suppl. 72): 1-28.
8. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51.
9. Camm AJ, Lip GY, De Caterina R et al. ESC Committee for Practice Guidelines. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
10. De Caterina R, Husted S, Wallentin L et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59: 1413-25.
11. van Walraven C, Jennings A, Oake N et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-66.
12. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-52.
13. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-105.
14. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-6.
15. Healey JS, Eikelboom J, Wallentin L et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. J Am Coll Cardiol 2010; 55: A4. E37.
16. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
17. Huisman MV, Lip GY, Diener HC et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-47.
18. National guidelines for the diagnosis and treatment of atrial fibrillation. Available at: http://scar-dio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed 25.10.2013. Russian (Национальные рекомендации по Диагностике и лечению фибрилляции предсердий. Доступно на: http://scar- dio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 25.10.2013)
19. Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-40.
20. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
21. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
22. Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 2012; 21: e11-2.
23. Sangha N, El Khoury R, Misra V, Lopez G. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 2012; 21: e5-8.
24. Testai FD. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 2013;22(6):894.
25. Weimar C, Hohnloser SH, Eikelboom JW, Diener HC. Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Curr Neurol Neurosci Rep 2012; 12: 17-23.
26. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-6.
27. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
28. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
Review
For citations:
Kosmacheva E.D., Kanorskiy S.G., Kastanayan A.A., Haylo N.V., Goltyapin D.B., Lipnitskaya E.A., Statsenko M.E. PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2013;9(5):551-556. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-5-551-556
Views:
744
.jpg)
Email this article 